Eckert & Ziegler to acquire Vitalea Science
Will enable the firm to expand into new markets
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its Californian subsidiary Eckert & Ziegler Isotope Products (EZIP), has agreed to purchase Vitalea Science, as part of the isotope technology firm’s entry into accelerator mass spectrometry (AMS) technology services. No financial details have been released.
Vitalea Science is a bioanalytical contract research organisation that provides services to researchers and clinicians in drug development supported by Accelerator Mass Spectrometry (AMS) technologies.
The firm also offers AMS services for the characterisation and identification of non-medical carbon based compounds.
Frank Yeager, Eckert & Ziegler Isotope Products’ president and ceo, said: ‘Vitalea is a unique company with a very unique capability built around the BioMICADAS device, which is the state-of-the-art in AMS technology.’
‘We believe that this capability will both allow Eckert & Ziegler to add value to our existing customer base and expand our area of expertise in new markets.’
Vitalea’s scientists include the original developers of AMS technology for applied bioscience at its location in Davis, California near the University of California Davis campus, a leading centre for research into AMS, PET tracers and other early phase medical studies.
Eckert & Ziegler Isotope Products is a manufacturer for nuclear imaging reference and calibration standards and a producer of radioactive components for industrial, scientific and medical applications.
The group employs nearly 600 people worldwide. Throughout all of its subsidiaries it generates yearly consolidated revenues in excess of US$146m (€116m).
